Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Elżbieta Senkus, S. Kyriakides, Shinji Ohno, et al.
Annals of Oncology (2015) Vol. 26, pp. v8-v30
Open Access | Times Cited: 1386

Showing 1-25 of 1386 citing articles:

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Peter Schmid, Sylvia Adams, Hope S. Rugo, et al.
New England Journal of Medicine (2018) Vol. 379, Iss. 22, pp. 2108-2121
Open Access | Times Cited: 3698
Breast cancer
Nadia Harbeck, Frédérique Penault‐Llorca, Javier Cortés, et al.
Nature Reviews Disease Primers (2019) Vol. 5, Iss. 1
Closed Access | Times Cited: 2258
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano, et al.
New England Journal of Medicine (2018) Vol. 380, Iss. 7, pp. 617-628
Open Access | Times Cited: 2168
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid, Hope S. Rugo, Sylvia Adams, et al.
The Lancet Oncology (2019) Vol. 21, Iss. 1, pp. 44-59
Closed Access | Times Cited: 1042
Translating RNA sequencing into clinical diagnostics: opportunities and challenges
Sara A. Byron, Kendall Van Keuren‐Jensen, David M. Engelthaler, et al.
Nature Reviews Genetics (2016) Vol. 17, Iss. 5, pp. 257-271
Open Access | Times Cited: 706
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 12, pp. 1688-1700
Closed Access | Times Cited: 534
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
Michael J. Duffy, Nadia Harbeck, M. Nap, et al.
European Journal of Cancer (2017) Vol. 75, pp. 284-298
Open Access | Times Cited: 455
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen Johnston, Nadia Harbeck, Roberto Hegg, et al.
Journal of Clinical Oncology (2020) Vol. 38, Iss. 34, pp. 3987-3998
Open Access | Times Cited: 418
Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
Hitisha Patel, Teeru Bihani
Pharmacology & Therapeutics (2017) Vol. 186, pp. 1-24
Open Access | Times Cited: 391
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
Francesca Poggio, Marco Bruzzone, Marcello Ceppi, et al.
Annals of Oncology (2018) Vol. 29, Iss. 7, pp. 1497-1508
Open Access | Times Cited: 384
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence
R. Charles Coombes, Karen Page, Raheleh Salari, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 14, pp. 4255-4263
Open Access | Times Cited: 383
Prognostic and predictive biomarkers in breast cancer: Past, present and future
Andrea Nicolini, Paola Ferrari, Michael J. Duffy
Seminars in Cancer Biology (2017) Vol. 52, pp. 56-73
Closed Access | Times Cited: 373
Advances in the Systemic Treatment of Triple-Negative Breast Cancer
J.M. Lebert, Renee Lester, Erin Powell, et al.
Current Oncology (2018) Vol. 25, Iss. 11, pp. 142-150
Open Access | Times Cited: 297
Lymph Node Metastasis Prediction from Primary Breast Cancer US Images Using Deep Learning
Liqiang Zhou, Xinglong Wu, Shuyan Huang, et al.
Radiology (2019) Vol. 294, Iss. 1, pp. 19-28
Open Access | Times Cited: 290
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer
Ivana Šestak, Richard Buus, Jack Cuzick, et al.
JAMA Oncology (2018) Vol. 4, Iss. 4, pp. 545-545
Open Access | Times Cited: 284
Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments
Tessa C. Gillespie, Hoda E. Sayegh, Cheryl L. Brunelle, et al.
Gland Surgery (2018) Vol. 7, Iss. 4, pp. 379-403
Open Access | Times Cited: 278
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
Özge Saatci, Aysegül Kaymak, Umar Raza, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 270
Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
Willemijne A.M.E. Schrijver, Karijn P.M. Suijkerbuijk, Carla H. van Gils, et al.
JNCI Journal of the National Cancer Institute (2017) Vol. 110, Iss. 6, pp. 568-580
Open Access | Times Cited: 247
Towards personalized treatment for early stage HER2-positive breast cancer
Kristina Goutsouliak, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, et al.
Nature Reviews Clinical Oncology (2019) Vol. 17, Iss. 4, pp. 233-250
Open Access | Times Cited: 245
Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients
Amirhessam Tahmassebi, Georg Wengert, Thomas H. Helbich, et al.
Investigative Radiology (2018) Vol. 54, Iss. 2, pp. 110-117
Open Access | Times Cited: 239
ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)
Shani Paluch‐Shimon, Fátima Cardoso, Ann H. Partridge, et al.
Annals of Oncology (2020) Vol. 31, Iss. 6, pp. 674-696
Open Access | Times Cited: 221
A systematic review of rehabilitation and exercise recommendations in oncology guidelines
Nicole L. Stout, Daniel Santa Mina, Kathleen Doyle Lyons, et al.
CA A Cancer Journal for Clinicians (2020) Vol. 71, Iss. 2, pp. 149-175
Open Access | Times Cited: 203
The new TNM-based staging of breast cancer
Gábor Cserni, Ewa Chmielik, Bálint Cserni, et al.
Virchows Archiv (2018) Vol. 472, Iss. 5, pp. 697-703
Closed Access | Times Cited: 200
Trastuzumab in the Treatment of Breast Cancer
Sofia Maximiano, Paulo Magalhães, Mara Pereira Guerreiro, et al.
BioDrugs (2016) Vol. 30, Iss. 2, pp. 75-86
Closed Access | Times Cited: 197
Luminal A Breast Cancer and Molecular Assays: A Review
Jennifer J. Gao, Sandra M. Swain
The Oncologist (2018) Vol. 23, Iss. 5, pp. 556-565
Open Access | Times Cited: 195
Page 1 - Next Page

Scroll to top